表紙
市場調查報告書

類風濕性關節炎 (RA) 治療藥的全球市場的預測 - 生技藥品,非生技藥品,NSAID,sDMARD:2020年∼2030年

Global Rheumatoid Arthritis Drugs Market Forecast 2020-2030: Biologics, Non-Biologics, NSAIDs, sDMARDs and Others

出版商 Visiongain Ltd 商品編碼 934307
出版日期 內容資訊 英文 236 Pages
商品交期: 最快1-2個工作天內
價格
類風濕性關節炎 (RA) 治療藥的全球市場的預測 - 生技藥品,非生技藥品,NSAID,sDMARD:2020年∼2030年 Global Rheumatoid Arthritis Drugs Market Forecast 2020-2030: Biologics, Non-Biologics, NSAIDs, sDMARDs and Others
出版日期: 2020年02月17日內容資訊: 英文 236 Pages
簡介

全球類風濕性關節炎 (RA) 治療藥市場在2018年估算達到580億美元,在預測期間內的後半預計以0.6%的年複合成長率成長。在次市場,2018年生技藥品市場區隔,佔全球類風濕性關節炎 (RA) 治療藥市場的85%。

本報告提供全球類風濕性關節炎 (RA) 治療藥市場相關調查分析,市場概要,市場動態,市場預測,主要企業等相關的系統性資訊。

目錄

第1章 報告概要

第2章 類風濕性關節炎 (RA) 治療藥的簡介

  • 所謂類風濕性關節炎 (RA)
  • 類風濕性關節炎 (RA)的原因
  • 疾病進展
  • 監測方法
  • 關於RA的治癒
  • 臨床試驗所使用的效能標準
  • RA的治療方法
  • RA相關的合併症
  • 類風濕性關節炎 (RA)的盛行率與發病率

第3章 類風濕性關節炎 (RA) 治療藥市場

  • 全球類風濕性關節炎 (RA) 治療藥市場:市場概要
  • 全球類風濕性關節炎 (RA) 治療藥市場:收益預測
  • 全球類風濕性關節炎 (RA) 治療藥市場:市場預測
  • 市場佔有率的變化:各市場區隔
  • RA的非生技藥品

第4章 類風濕性關節炎 (RA) 市場上主要治療藥

  • 類風濕性關節炎 (RA) 市場上的主要治療藥
  • Humira
  • Enbrel
  • Remicade
  • Rituxan
  • Simponi (golimumab)
  • Orencia
  • Actemra/RoActemra
  • Cimzia
  • Celebrex
  • Xeljanz
  • Arcoxia

第5章 主要國家市場

  • 全球類風濕性關節炎 (RA) 治療藥市場地理明細
  • 全球類風濕性關節炎 (RA) 治療藥市場:各地區預測

第6章 北美的類風濕性關節炎 (RA) 治療藥市場

  • 美國
  • 加拿大

第7章 歐洲的類風濕性關節炎 (RA) 治療藥市場

  • 市場佔有率的變化:各國
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他

第8章 亞太地區的類風濕性關節炎 (RA) 治療藥市場

  • 日本
  • 中國
  • 印度
  • 其他

第9章 南美的類風濕性關節炎 (RA) 治療藥市場

  • 巴西
  • 墨西哥
  • 其他

第10章 中東、非洲的類風濕性關節炎 (RA) 治療藥市場

  • 沙烏地阿拉伯
  • 南非
  • 其他

第11章 類風濕性關節炎 (RA)的研究開發平台

第12章 類風濕性關節炎 (RA) 治療藥市場主要企業

  • 主要企業的簡介
  • AbbVie
  • F. Hoffmann-La Roche Ltd (Roche)
  • Johnson & Johnson
  • Amgen, Inc.
  • Pfizer
  • Merck & Co., Inc.
  • Bristol-Myers Squibb (BMS)
  • UCB
  • Eli Lilly and Company
  • Novartis AG
  • Sanofi S.A. (Sanofi)

第13章 慢性風濕病 (RA) 市場定量分析

第14章 結論

附錄

目錄
Product Code: PHA0671

The global Rheumatoid Arthritis market is estimated to have reached $58bn in 2018 and is expected to grow at a CAGR of 0.6% in the second half of the forecast period. In 2018, the biologics submarket held 85% of the global Rheumatoid Arthritis market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 236-page report you will receive 180 tables and 121 figures- all unavailable elsewhere.

The 236-page report provides clear detailed insight into the rheumatoid arthritis market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope:

Global Rheumatoid Arthritis Market forecast from 2020-2030

Revenue forecasts for the Rheumatoid Arthritis Market by Drug Class from 2020-2030:

  • Biologics
  • Non-Biologics: NSAIDs, sDMARDs, Others

Revenue forecasts for the Rheumatoid Arthritis Market by Drugs from 2020-2030:

  • Humira
  • Enbrel
  • Remicade
  • Rituxan/MabThera
  • Simponi/Simponi Aria
  • Orencia
  • Actemra/Roactemra
  • Cimzia
  • Celebrex
  • Xeljanz
  • Arcoxia
  • Others

Revenue forecasts for the Rheumatoid Arthritis Market by Region from 2020-2029:

  • North America: U.S., Canada
  • Europe: Germany, UK, France, Italy, Spain, Russia, Rest of Europe
  • Asia-Pacific: Japan, China, India, Rest of Asia-Pacific
  • Latin America: Brazil, Mexico, Rest of Latin America
  • Middle East & Africa: Saudi Arabia, South Africa, Rest of MEA

Profiles of these selected leading companies:

  • AbbVie
  • Amgen, Inc.
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Merck & Co.
  • Novartis AG
  • Pfizer
  • Sanofi S.A.
  • UCB

Analysis of the Drivers, Restraints, Opportunities and Threats of the global rheumatoid arthritis drugs market

The report also includes SWOT Analysis of the Global rheumatoid arthritis drugs market

Key questions answered by this report:

  • How is the Rheumatoid Arthritis drugs market evolving?
  • What is driving and restraining the Rheumatoid Arthritis drugs market?
  • What are the market shares of each segment of the overall Rheumatoid Arthritis drugs market in 2018?
  • How will each Rheumatoid Arthritis drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030?
  • How will the market shares for each Rheumatoid Arthritis drugs submarket develop from 2020 to 2030?
  • Which individual therapies will prevail and how will these shifts be responded to?
  • What will be the main driver for the overall market from 2020 to 2030?
  • How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030?
  • Who are the leading players and what are their prospects over the forecast period?
  • How will the industry evolve during the period between 2020 and 2030?

Visiongain's study is intended for anyone requiring commercial analyses for the Global Rheumatoid Arthritis Drugs Market. You find data, trends and predictions.

Buy our report today Global Rheumatoid Arthritis Drugs Market Forecast 2020-2030: Prospects for Biologics, Non-Biologics (NSAIDs, sDMARDs and Others).

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Global Rheumatoid Arthritis Drugs Market Overview
  • 1.2 Overview of Findings
  • 1.3 Structure of the Report
  • 1.4 Global Rheumatoid Arthritis Drugs Market Segmentation
  • 1.5 Why You Should Read This Report
  • 1.6 How This Report Delivers
  • 1.7 Key Questions Answered by This Analytical Report
  • 1.8. Who is This Report For?
  • 1.9 Methodology
  • 1.10 Associated Visiongain Reports
  • 1.11 About Visiongain

2. Introduction to Rheumatoid Arthritis Drugs

  • 2.1 What is Rheumatoid Arthritis?
  • 2.2 What Causes Rheumatoid Arthritis?
  • 2.3. How Does the Disease Develop?
  • 2.4. How Can It Be Monitored?
  • 2.5. Can RA Be Cured?
  • 2.6. Performance Criteria Used in Clinical Trials
    • 2.6.1. ACR Criteria for Drug Efficacy
    • 2.6.2. HAQ-DI Measures Daily Activities
    • 2.6.3. mSS Assesses Disease on X-Ray
    • 2.6.4. DAS28 For Disease Severity
  • 2.7. How is RA Treated?
    • 2.7.1 Biologic DMARDs Are the Dominant Source of Revenue
    • 2.7.2 Synthetic DMARDs are the Mainstay of Treatment
    • 2.7.3 Others
      • 2.7.3.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
      • 2.7.3.2 Corticosteroids for Rapid Anti-Inflammatory Effect
      • 2.7.3.3 Analgesics for Rapid Pain Relief
  • 2.8 Comorbid Conditions Associated with RA
  • 2.9 Prevalence and Incidence Rates of Rheumatoid Arthritis

3. Rheumatoid Arthritis Drugs Market, 2020-2030 P

  • 3.1 The Global Rheumatoid Arthritis Drugs Market: Market Overview
  • 3.2 Global Rheumatoid Arthritis Drugs Market: Revenue Forecast 2020-2030
  • 3.3 Global Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030
  • 3.4 Changing Market Shares by Segment 2020-2030
  • 3.5 Non-Biologics for RA
    • 3.5.1 NSAIDs: Revenue Forecast, 2020-2030
    • 3.5.2 Synthetic DMARDs (sDMARDs): Revenue Forecast, 2018-2030
    • 3.5.3 Others: Revenue Forecast, 2018-2030

4. Leading Drugs in the Rheumatoid Arthritis Market 2020-2030

  • 4.1 The Main Drugs in the Rheumatoid Arthritis Market, 2018
  • 4.2 Humira: A Major Source of Revenue for AbbVie
    • 4.2.1 Adalimumab Biosimilars
    • 4.2.2 Humira: Sales Forecast 2020-2030
  • 4.3 Enbrel: Amgen's Revenue Protected Until 2030
    • 4.3.1 Etanercept Biosimilars
    • 4.3.2 Enbrel: Revenue Forecast 2020-2030
  • 4.4 Remicade: Facing Significant Competition from Biosimilars
    • 4.4.1 Infliximab Biosimilars
    • 4.4.2 Remicade: Revenue Forecast 2018-2030
  • 4.5 Rituxan: Facing Declining Market Share
    • 4.5.1 Rituximab Biosimilars
    • 4.5.2 Rituxan: Revenue Forecast 2018-2030
  • 4.6 Simponi (golimumab): Market Share Remaining Stable
    • 4.6.1 Simponi/Simponi Aria: Revenue Forecast 2018-2030
  • 4.7 Orencia: Additional Indications Being Explored
    • 4.7.1 Abatacept Biosimilars
    • 4.7.2 Orencia: Revenue Forecast 2018-2030
  • 4.8 Actemra/RoActemra: First IL-6R Inhibitor Approved for RA
    • 4.8.1 Tocilizumab Biosimilars
    • 4.8.2 Actemra/RoActemra: Revenue Forecast 2018-2030
  • 4.9 Cimzia: Reliable Source of Income for UCB
    • 4.9.1 Certolizumab Biosimilars
    • 4.9.2 Cimzia: Revenue Forecast 2018-2030
  • 4.10 Celebrex: Facing Generic Competition
    • 4.10.1 Celebrex: Revenue Forecast 2018-2030
  • 4.11 Xeljanz: Good Opportunity for Revenue Growth
    • 4.11.1 Xeljanz: Revenue Forecast 2018-2030
  • 4.12 Arcoxia: Sales Revenue Already Declining
    • 4.12.1 Arcoxia: Revenue Forecast 2018-2030

5. Leading National Markets 2020-2030

  • 5.1. Geographical Breakdown of the World Rheumatoid Arthritis Drugs Market
  • 5.2 World Rheumatoid Arthritis Drugs Market: Regional Forecast 2020-2030
    • 5.2.1 How Will Regional Market Shares Change to 2030?

6. North America Rheumatoid Arthritis Drugs Market, 2020-2030

  • 6.1. US Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030
  • 6.2. Canada Rheumatoid Arthritis Drugs Market: Trends and Developments

7. Europe Rheumatoid Arthritis Drugs Market 2020-2030

  • 7.1 Europe Markets: Changing Market Shares by Country, 2020-2030
  • 7.2. Germany Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030
  • 7.3. France Rheumatoid Arthritis Drugs Market: Trends and Developments
  • 7.4. U.K. Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030
  • 7.5. Italy Rheumatoid Arthritis Drugs Market: Trends and Developments
  • 7.6. Spain Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030
  • 7.7. Russia Rheumatoid Arthritis Drugs Market: Trends and Developments
  • 7.8. Rest of Europe Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030

8. Asia-Pacific Rheumatoid Arthritis Drugs Market 2020-2030

  • 8.1. Japan Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030
  • 8.2. China Rheumatoid Arthritis Drugs Market: Trends and Developments
  • 8.3. India Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030
  • 8.4. Rest of Asia Pacific Rheumatoid Arthritis Drugs Market: Trends and Developments

9. Latin America Rheumatoid Arthritis Drugs Market, 2020-2030

  • 9.1. Brazil Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030
  • 9.2. Mexico Rheumatoid Arthritis Drugs Market: Trends and Developments
  • 9.3. Rest of Latin America Rheumatoid Arthritis Drugs Market: Trends and Developments

10. Middle East & Africa Rheumatoid Arthritis Drugs Market, 2020-2030

  • 10.1. Saudi Arabia Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030
  • 10.2. South Africa Rheumatoid Arthritis Drugs Market: Trends and Developments
  • 10.3. Rest of Middle East & Africa Rheumatoid Arthritis Drugs Market: Trends and Developments

11. Rheumatoid Arthritis R&D Pipeline 2019

12. Leading Companies in the Rheumatoid Arthritis Drugs Market, 2019

  • 12.1 Introduction to the Leading Companies
  • 12.2 AbbVie: Secured Multiple Patents for Humira
    • 12.2.1 Overview
    • 12.2.2 AbbVie: Rheumatoid Arthritis Drugs Product Portfolio
    • 11.2.3 AbbVie: Financial Overview
    • 12.2.4 AbbVie: Recent Transactions Summary
  • 12.3 F. Hoffmann-La Roche Ltd (Roche)
    • 12.3.1 Overview
    • 12.3.2 Roche: Financial Overview
    • 12.3.3 Recent Transactions Summary
  • 12.4 Johnson & Johnson
    • 12.4.1 Overview
    • 12.4.2 Johnson & Johnson: Financial Overview
    • 12.4.3 Johnson & Johnson: Recent Transactions Summary
  • 11.5. Amgen, Inc.
    • 12.5.1 Overview
    • 12.5.2 Amgen Inc.: Financial Overview
    • 12.5.3. Amgen Inc.: Recent Transactions Summary
  • 12.6. Pfizer: Actively Developing Biosimilars
    • 12.6.1 Overview
    • 12.6.2 Pfizer, Inc.: Financial Overview
    • 12.6.3 Pfizer, Inc.: Recent Transactions Summary
  • 12.7 Merck & Co., Inc.: Remicade Sales in Decline
    • 12.7.1. Overview
    • 12.7.2 Merck & Co., Inc.: Financial Overview
    • 12.7.3 Merck & Co., Inc.: Recent Transactions Summary
  • 12.8. Bristol-Myers Squibb (BMS): Exploring Additional Indications for Orencia
    • 12.8.1. Overview
    • 12.8.2 Bristol-Myers Squibb: Financial Overview
    • 12.8.3 Bristol-Myers Squibb: Recent Developments
  • 12.9. UCB: Reliant on Cimzia Revenue
    • 12.9.1 Overview
    • 12.9.2 UCB: Financial Overview
    • 12.9.3 UCB: Recent Developments
  • 12.10. Eli Lilly and Company
    • 12.10.1 Eli Lilly and Company: Rheumatoid Arthritis Drugs Portfolio
    • 12.10.2 Eli Lilly and Company: Financial Overview
    • 12.10.3 Eli Lilly and Company: Recent Transactions Summary
  • 12.11. Novartis AG
    • 12.11.1 Novartis AG: Rheumatoid Arthritis Drugs Portfolio
    • 12.11.2 Novartis AG: Financial Overview
    • 12.11.3 Novartis AG: Recent Transactions Summary
  • 12.12. Sanofi S.A. (Sanofi)
    • 12.12.1 Sanofi S.A.: Rheumatoid Arthritis Drugs Portfolio
    • 12.12.2 Sanofi: Financial Overview
    • 12.12.3 Sanofi S.A.: Recent Transactions Summary

13. Qualitative Analysis of the Rheumatoid Arthritis Market

  • 13.1 Strengths and Weaknesses of the Rheumatoid Arthritis Market
    • 13.1.1 Strengths
      • 13.1.1.1 Number of Elderly Patients Expected to Rise
      • 13.1.1.2 Biologics Already Recognised as a Valuable Part of Treatment
      • 13.1.1.3 Biologics Used in RA Often Have Multiple Indications
    • 13.1.2 Weaknesses
      • 13.1.2.1 Some Patients Have an Inadequate Treatment Response
      • 13.1.2.2. Efficacy of Drugs Can Diminish Over Time
    • 13.1.3. Opportunities
      • 13.1.3.1 Need for Effective Drugs with Better Safety Profiles
      • 13.1.3.2 Need for Less Invasive Route of Administration
    • 13.1.4. Threats
      • 13.1.4.1 High Number of Products Will Saturate Market
      • 13.1.4.2 Competition from Biosimilars Will Increase
  • 13.2 Social, Technological, Economic and Political Factors Affecting the Rheumatoid Arthritis Market (STEP Analysis)
    • 13.2.1 Social Factors Influencing the Rheumatoid Arthritis Market
    • 13.2.2 Technological Factors Influencing the Rheumatoid Arthritis Market
    • 13.2.3 Economic Factors Influencing the Rheumatoid Arthritis Market
    • 13.2.4 Political Factors Influencing the Rheumatoid Arthritis Market
      • 13.2.4.1 Government Pressure to Control Costs
      • 13.2.4.2 Inter-country Variability in Biosimilar Approval Process

14. Conclusions

  • 14.1 Overview of Current Market Conditions and Market Forecast
  • 14.2 Biologics Will Remain Dominant Drug Class but their Market Share Will Drop More than 20%
  • 14.3 Enbrel Will Overtake Humira as the Leading Drug
  • 14.4 Leading Regions in the Rheumatoid Arthritis Market in 2018
  • 14.5 Trends in the RA Drugs Market

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Table

  • Table 2.1 Biologic Agents and Mechanism of Action
  • Table 2.2 Comorbidities Associated with RA in Different Organs
  • Table 2.3 Prevalence rate of RA in Different Countries
  • Table 3.1 Rheumatoid Arthritis Drugs Market by Submarket, 2018
  • Table 3.2 The Global Rheumatoid Arthritis Drugs Market: Revenue ($m) and Market Shares (%) by Type, 2018 and 2019
  • Table 3.3 Global Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 3.4 Global Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 3.5 Global Rheumatoid Arthritis Drugs Market by Drugs Class: CAGR (%), 2020- 2024, 2024-2030, 2020-2030
  • Table 3.6 Non-Biologics for Rheumatoid Arthritis Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 3.7 NSAIDs for Rheumatoid Arthritis Market Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2018-2030
  • Table 3.8 sDMARDs for Rheumatoid Arthritis Market Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2018-2030
  • Table 3.9 Others for Rheumatoid Arthritis Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2018-2030
  • Table 4.1 Global Rheumatoid Arthritis Market by Drugs Classs: Revenue ($m), and Market Share (%), 2018
  • Table 4.2 The Main Drugs in the Rheumatoid Arthritis Market Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2018-2030
  • Table 4.3 The Main Drugs in the Rheumatoid Arthritis Market Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2018-2030
  • Table 4.4 The Main Drugs in the Rheumatoid Arthritis Market Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2018-2030
  • Table 4.5 Humira: Key Facts
  • Table 4.6 Adalimumab Biosimilars: Current Status, 2019
  • Table 4.7 Global Humira Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030
  • Table 4.8 Enbrel: Key Facts
  • Table 4.9 Etanercept Biosimilars: Current Status, 2019
  • Table 4.10 Global Enbrel Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018- 2030
  • Table 4.11 Remicade: Key Facts
  • Table 4.12 Infliximab Biosimilars: Current Status, 2019
  • Table 4.13 Global Remicade Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030
  • Table 4.14 Rituxan: Key Facts
  • Table 4.15 Rituximab Biosimilars: Current Status, 2019
  • Table 4.16 Global Rituxan Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030
  • Table 4.17 Simponi: Key Facts
  • Table 4.18 Global Simponi/Simponi Aria Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030
  • Table 4.19 Orencia: Key Facts
  • Table 4.20 Global Orencia Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030
  • Table 4.21 Actemra/RoActemra: Key Facts
  • Table 4.22 Global Actemra/RoActemra Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030
  • Table 4.23 Cimzia: Key Facts
  • Table 4.24 Global Cimzia Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030
  • Table 4.25 Celebrex: Key Facts
  • Table 4.26 Global Celebrex Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030
  • Table 4.27 Xeljanz: Key Facts
  • Table 4.28 Global Xeljanz Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030
  • Table 4.29 Arcoxia: Key Facts
  • Table 4.30 Global Arcoxia Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030
  • Table 5.1 Global Rheumatoid Arthritis Drugs Market by Region: Revenue ($ m), 2018 and 2019
  • Table 5.2 Global Rheumatoid Arthritis Drugs Market Forecast: Revenues ($ m), AGR (%), CAGR (%), 2018-2030
  • Table 5.3 Global Rheumatoid Arthritis Drugs Market by Region: CAGR (%), 2020-2024, 2024-2030, 2020-2030
  • Table 5.4 Global Rheumatoid Arthritis Drugs Market by Region: Market Share (%), 2019, 2024, 2030
  • Table 6.1 North America Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 6.2 North America Rheumatoid Arthritis Drugs (Non-Biologics) Market Forecast by Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 6.3 North America Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues ($ m), AGR (%), CAGR (%), 2018-2030
  • Table 6.4 U.S.Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 6.5 Canada Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 7.1 Europe Rheumatoid Arthritis Drugs Market by Country/Sub-region: Revenue ($m) and Market Share (%), 2018
  • Table 7.2 Europe Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 7.3 Europe Rheumatoid Arthritis Drugs (Non-Biologics) Market Forecast by Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 7.4 Global Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 7.5 Europe Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 7.6 Global Rheumatoid Arthritis Drugs Market by Region: CAGR (%), 2020-2024, 2024-2030, and 2020-2030
  • Table 7.7 Germany Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues ($ m), AGR (%), CAGR (%), 2018-2030
  • Table 7.8 France Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 7.9 U.K.Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 7.10 Italy Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 7.11 Spain Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 7.12 Russia Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 7.13 Rest of Europe Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues ($ m), AGR (%), CAGR (%), 2018-2030
  • Table 8.1 Global Rheumatoid Arthritis Drugs Market by Country/Sub-region: Revenue ($ m) and Market Share (%), 2018
  • Table 8.2 Asia Pacific Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 8.3 Asia Pacific Rheumatoid Arthritis Drugs (Non-Biologics) Market Forecast by Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 8.4 Asia-Pacific Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 8.5 Japan Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 8.6 China Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 8.7 India Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 8.8 Rest of Asia Pacific Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 9.1 Latin America Rheumatoid Arthritis Drugs Market by Country/Sub-region: Revenue ($m) and Market Share (%), 2018
  • Table 9.2 Latin America Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 9.3 Latin America Rheumatoid Arthritis Drugs (Non-Biologics) Market Forecast by Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 9.4 Latin America Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 9.5 Brazil Rheumatoid Arthritis Drugs Market Forecast, By Country: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 9.6 Mexico Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 9.7 Rest of Latin America Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 10.1 Middle East & Africa Rheumatoid Arthritis Drugs Market by Country/Sub- region: Revenue ($ m) and Market Share (%), 2018
  • Table 10.2 Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues ($ m), AGR (%), CAGR (%), 2018-2030
  • Table 10.3 Middle East & Africa Rheumatoid Arthritis Drugs (Non-Biologics) Market Forecast by Segment: Revenues ($ m), AGR (%), CAGR (%), 2018-2030
  • Table 10.4 Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 10.5 Saudi Arabia Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 10.6 South Africa Rheumatoid Arthritis Drugs Market Forecast: Revenues ($ m), AGR (%), CAGR (%), 2018-2030
  • Table 10.7 Rest of Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
  • Table 11.1 Pipeline R&D Products, 2019
  • Table 11.2 Other RA Pipeline R&D Products, 2019
  • Table 12.1 Leading Companies in the RA Drug Market: Revenue ($m) and Market Share (%), 2018
  • Table 12.2 AbbVie: Breakdown of Revenue ($m,%) by RA Drug, 2018
  • Table 12.3 AbbVie: Overview, 2019
  • Table 12.4 AbbVie: Revenue ($m), AGR (%), 2014-2018
  • Table 12.5 F.Hoffmann-La Roche AG:: Breakdown of Revenue ($m,%) by RA Drug, 2018
  • Table 12.6. Roche: Overview, 2019
  • Table 12.7 Roche: Revenue ($m), AGR (%), 2014-2018
  • Table 12.8 Johnson & Johnson: Breakdown of Revenue ($m,%) by RA Drug, 2018
  • Table 12.9. Johnson & Johnson: Overview, 2019
  • Table 12.10 Johnson & Johnson: Revenue ($m), AGR (%), 2014-2018
  • Table 12.11 Amgen: Breakdown of Revenue ($m,%) by RA Drug, 2018
  • Table 12.12 Amgen, Inc.: Overview, 2019
  • Table 12.13 Amgen Inc.: Revenue ($m), AGR (%), 2014-2018
  • Table 12.14 Pfizer: Breakdown of Revenue ($m,%) by RA Drug, 2018
  • Table 12.15 Pfizer, Inc.: Overview, 2019
  • Table 12.16 Pfizer, Inc.: Revenue ($m), AGR (%), 2014-2018
  • Table 12.17 Merck & Co., Inc.: Breakdown of Revenue ($m,%) by RA Drug, 2018
  • Table 12.18 Merck & Co., Inc.: Overview, 2019
  • Table 12.19 Merck & Co., Inc.: Revenue ($m), AGR (%), 2014-2018
  • Table 12.20 Bristol-Myers Squibb: Breakdown of Revenue ($m,%) by RA Drug, 2018
  • Table 12.21 Bristol-Myers Squibb: Overview, 2019
  • Table 12.22 Bristol-Myers Squibb: Revenue ($m), AGR (%), 2014-2018
  • Table 12.23 UCB: Breakdown of Revenue ($m,%) by RA Drug, 2018
  • Table 12.24 UCB: Overview, 2019
  • Table 12.25 UCB: Revenue ($m), AGR (%), 2014-2018
  • Table 12.26 Eli Lilly and Company: Overview, 2019
  • Table 12.27 Eli Lilly and Company: Revenue ($m), AGR (%), 2014-2018
  • Table 12.28 Novartis AG: Overview, 2019
  • Table 12.29 Novartis AG: Revenue ($m), AGR (%), 2014-2018
  • Table 12.30 Sanofi S.A.: Overview, 2019
  • Table 12.31 Sanofi: Revenue ($m), AGR (%), 2014-2018
  • Table 13.1 SWOT Analysis of the Global Rheumatoid Arthritis Market, 2020-2030
  • Table 13.2 Social, Technological, Economic and Political Factors Influencing the RA Market, 2018-2030
  • Table 14.1 Global Rheumatoid Arthritis Market Forecast: Revenue ($m), and CAGR (%), 2018, 2024 and 2030
  • Table 14.2 Global Rheumatoid Arthritis Market by Drugs Class: CAGR (%), 2018, 2024, 2030
  • Table 14.3 Global Rheumatoid Arthritis Market by Region: CAGR (%), 2018, 2024, 2030

List of Figure

  • Figure 1.1 Global Rheumatoid Arthritis Drugs Market Segmentation Overview
  • Figure 3.1 Rheumatoid Arthritis Drugs Market: Market Share (%) by Indication, 2018
  • Figure 3.2 Rheumatoid Arthritis Drugs Market: Market Share (%) by Class, 2018
  • Figure 3.3 Global Rheumatoid Arthritis Drugs Market Forecast: Revenue ($ m), AGR (%), 2018-2030
  • Figure 3.4 The Global Rheumatoid Arthritis Drugs Market Forecast by Drugs Class, 2018
  • Figure 3.5 The Global Rheumatoid Arthritis Drugs Market Forecast by Drugs Class, 2019
  • Figure 3.6 The Global Rheumatoid Arthritis Drugs Market Forecast by Drugs Class: CAGR (%), 2020-2030
  • Figure 3.7 The Rheumatoid Arthritis Drugs Market Segments: Revenue ($m) Forecast, 2018-2030
  • Figure 3.8 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2018
  • Figure 3.9 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2024
  • Figure 3.10 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2030
  • Figure 3.11 Non-Biologics for Rheumatoid Arthritis: Revenue ($m) Forecasts by Segment, 2018-2030
  • Figure 3.12 Non-Biologics for Rheumatoid Arthritis: Market Share (%), 2018
  • Figure 3.13 Non-Biologics for Rheumatoid Arthritis: Market Share (%), 2024
  • Figure 3.14 Non-Biologics for Rheumatoid Arthritis: Market Share (%), 2030
  • Figure 3.15 Global NSAIDs Rheumatoid Arthritis Drugs Market Forecast: Revenue ($ m), AGR (%), 2018-2030
  • Figure 3.16 sDMARDs for Rheumatoid Arthritis Market Forecasts: Revenue ($ m), AGR (%), 2018-2030
  • Figure 3.17 Others Drugs Market Forecast: Revenue ($ m), AGR (%), 2018-2030
  • Figure 4.1 The Main Drugs in the Rheumatoid Arthritis Market: Market Shares (%), 2018
  • Figure 4.2 Global Humira Market Forecast: Revenue ($m) AGR (%), 2018-2030
  • Figure 4.3 Global Enbrel Market Forecast: Revenue ($m) AGR (%), 2018-2030
  • Figure 4.4 Global Remicade Market Forecast: Revenue ($m) AGR (%), 2018-2030
  • Figure 4.5 Global Rituxan Market Forecast: Revenue ($m) AGR (%), 2018-2030
  • Figure 4.6 Global Simponi/Simponi Aria Market Forecast: Revenue ($m) AGR (%), 2018-2030
  • Figure 4.7 Global Orencia Market Forecast: Revenue ($m) AGR (%), 2018-2030
  • Figure 4.8 Global Actemra/RoActemra Market Forecast: Revenue ($m) AGR (%), 2018-2030
  • Figure 4.9 Global Cimzia Market Forecast: Revenue ($m) AGR (%), 2018-2030
  • Figure 4.10 Global Celebrex Market Forecast: Revenue ($m) AGR (%), 2018-2030
  • Figure 4.11 Global Xeljanz Market Forecast: Revenue ($m) AGR (%), 2018-2030
  • Figure 4.12 Global Arcoxia Market Forecast: Revenue ($m) AGR (%), 2018-2030
  • Figure 5.1 World Rheumatoid Arthritis Drugs Market: Revenues ($ m) by Region, 2018
  • Figure 5.2 World Rheumatoid Arthritis Drugs Market: Revenues ($m) by Region, 2019
  • Figure 5.3 Global Rheumatoid Arthritis Drugs Market Forecast: Revenue ($ m), AGR (%), 2018-2030
  • Figure 5.4 World Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2019
  • Figure 5.5 World Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2024
  • Figure 5.6 World Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2030
  • Figure 6.1 North America Rheumatoid Arthritis Drugs Market Forecast: Revenue ($m), AGR (%), 2018-2030
  • Figure 6.2 North America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2019
  • Figure 6.3 North America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2024
  • Figure 6.4 North America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2030
  • Figure 6.5 U.S. Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
  • Figure 6.6 Canada Rheumatoid Arthritis Drugs Market Forecast: Revenues($m), AGR (%), 2018-2030
  • Figure 7.1 Europe Rheumatoid Arthritis Drugs Market: Revenues ($m) by Country/Sub-region, 2018
  • Figure 7.2 Europe Rheumatoid Arthritis Drugs Market Forecast: Revenue ($m), AGR (%), 2018-2030
  • Figure 7.3 Europe Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2018
  • Figure 7.4 Europe Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2024
  • Figure 7.5 Europe Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2030
  • Figure 7.6 Germany Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
  • Figure 7.7 France Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
  • Figure 7.8 U.K. Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
  • Figure 7.9 Italy Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
  • Figure 7.10 Spain Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
  • Figure 7.11 Russia Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
  • Figure 7.12 Rest of Europe Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
  • Figure 8.1 Asia Pacific Rheumatoid Arthritis Drugs Market: Revenues ($m) by Country/Sub-region, 2018
  • Figure 8.2 Asia Pacific Rheumatoid Arthritis Drugs Market Forecast: Revenue ($ m), AGR (%), 2018-2030
  • Figure 8.3 Asia Pacific Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2018
  • Figure 8.4 Asia Pacific Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2024
  • Figure 8.5 Asia Pacific Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2030
  • Figure 8.6 Japan Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
  • Figure 8.7 China Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
  • Figure 8.8 India Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
  • Figure 8.9 Rest of Asia Pacific Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
  • Figure 9.1 Latin America Rheumatoid Arthritis Drugs Market: Revenues ($m) by Country/Sub-region, 2018
  • Figure 9.2 Latin America Rheumatoid Arthritis Drugs Market Forecast: Revenue ($m), AGR (%), 2018-2030
  • Figure 9.3 Latin America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2018
  • Figure 9.4 Latin America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2024
  • Figure 9.5 Latin America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2030
  • Figure 9.6 Brazil Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
  • Figure 9.7 Mexico Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
  • Figure 9.6 Rest of Latin America Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
  • Figure 10.1 Middle East & Africa (MEA) Rheumatoid Arthritis Drugs Market: Revenues ($m) by Country/Sub-region, 2018
  • Figure 10.2 Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast: Revenue ($m), AGR (%), 2018-2030
  • Figure 10.3 Middle East & Africa Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2018
  • Figure 10.4 Middle East & Africa Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2024
  • Figure 10.5 Middle East & Africa Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2030
  • Figure 10.6 Saudi Arabia Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
  • Figure 10.7 South Africa Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
  • Figure 10.8 Rest of Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
  • Figure 12.1 AbbVie: Revenue ($m), AGR (%), 2014-2018
  • Figure 12.2 AbbVie: Business Segment Revenue Share (%), 2018
  • Figure 12.3 AbbVie: Region Revenue Share (%), 2018
  • Figure 12.4 Roche: Revenue ($m), AGR (%), 2014-2018
  • Figure 12.5 Roche: Business Segment Revenue Share (%), 2018
  • Figure 12.6 Roche: Breakdown of Revenue (%) by Pharmaceuticals Drug, 2018
  • Figure 12.7 Johnson & Johnson: Revenue ($m), AGR (%), 2014-2018
  • Figure 12.8 Johnson & Johnson: by Business Segments Revenue Share (%), 2018
  • Figure 12.9 Johnson & Johnson: by Region Revenue Share (%), 2018
  • Figure 12.10 Amgen Inc.: Revenue ($m), AGR (%), 2014-2018
  • Figure 12.11 Amgen Inc.: Business Segment Revenue Share (%), 2018
  • Figure 12.12 Amgen Inc.: Region Revenue Share (%), 2018
  • Figure 12.13 Pfizer, Inc.: Revenue ($m), AGR (%), 2014-2018
  • Figure 12.14 Pfizer, Inc.: Business Segment Revenue Share (%), 2018
  • Figure 12.15 Pfizer, Inc: Region Revenue Share (%), 2018
  • Figure 12.16 Merck & Co., Inc.: Revenue ($m), AGR (%), 2014-2018
  • Figure 12.17 Merck & Co., Inc.: Business Segment Revenue Share (%), 2018
  • Figure 12.18 Merck & Co., Inc.: by Region Revenue Share (%), 2018
  • Figure 12.19 Bristol-Myers Squibb: Revenue ($m), AGR (%), 2014-2018
  • Figure 12.20 Bristol-Myers Squibb: Business Segment Revenue Share (%), 2018
  • Figure 12.21 Bristol-Myers Squibb: by Region Revenue Share (%), 2018
  • Figure 12.22 UCB: Revenue ($m), AGR (%), 2014-2018
  • Figure 12.23 UCB: Business Segment Revenue Share (%), 2018
  • Figure 12.24 UCB: by Region Revenue Share (%), 2018
  • Figure 12.25 Eli Lilly and Company: Revenue ($m), AGR (%), 2014-2018
  • Figure 12.26 Eli Lilly and Company: Business Segment Revenue Share (%), 2018
  • Figure 12.27 Eli Lilly and Company: by Region Revenue Share (%), 2018
  • Figure 12.28 Novartis AG: Revenue ($m), AGR (%), 2014-2018
  • Figure 12.29 Novartis AG: Business Segment Revenue Share (%), 2018
  • Figure 12.30 Novartis AG: by Region Revenue Share (%), 2018
  • Figure 12.31 Sanofi: Revenue ($m), AGR (%), 2014-2018
  • Figure 12.32 Sanofi: Business Segment Revenue Share (%), 2018
  • Figure 12.33 Sanofi: by Region Revenue Share (%), 2018
  • Figure 14.1 RA Drugs Market: Comparison of Revenue ($m Forecasts for Total Market and Market for RA Indication, 2018-2030
  • Figure 14.2 Global Rheumatoid Arthritis Market Forecast: Revenue ($m) 2018, 2024, 2030
  • Figure 14.3 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2018
  • Figure 14.4 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2024
  • Figure 14.5 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2030
  • Figure 14.6 The Leading Drugs in the RA Market: Revenue ($m) Forecasts, 2018, 2024, 2030
  • Figure 14.7 The Global Rheumatoid Arthritis Market Forecast by Region: Revenue ($m), 2018, 2024, 2030

List of Companies Mentioned in the Report:

  • 4SC
  • AbbVie
  • Abivax
  • Ablynx NV Sanofi
  • Adheron Therapeutics, Inc.
  • Akari Therapeutics Plc
  • Alder Biopharmaceuticals
  • Amgen
  • Anacor
  • Araim Pharmaceuticals, Inc.
  • argenx
  • Artax Biopharma, Inc.
  • Astellas Pharma Inc
  • Baxalta Incorporated
  • Biocon Ltd.
  • Biogen
  • Bioxpress Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cadila Healthcare
  • Cambridge Biotechnology Ltd.
  • CASI Pharmaceuticals
  • Catabasis Pharmaceuticals
  • Celltex Therapeutics Corp.
  • Celltrion, Inc.
  • ChemoCentryx
  • Chugai Pharmaceutical Co., Ltd.
  • Coherus BioSciences Inc
  • Covagen AG
  • Cyclacel Pharmaceuticals
  • Cyxone AB
  • Daiichi Sankyo
  • DePuy Synthes
  • Dr Reddy's Laboratories
  • Eli Lilly
  • Epirus Biopharmaceuticals
  • Five Prime Therapeutics
  • Fresenius Kabi
  • Fujifilm Corporation
  • Galapagos NV
  • Galderma
  • Genentech
  • Gerresheimer
  • Giaconda Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Hanmi Pharmaceutical Co Ltd.
  • Hospira
  • Immunomedics
  • Incyte Corporation
  • Innate Pharma - IPO Pending
  • Intas
  • Italfarmaco SpA
  • Izana Bioscience Ltd.
  • Janssen Biologics
  • Johnson & Johnson
  • Kadmon Holdings
  • Kyowa Hakko Kirin Co Ltd
  • Lycera Corporation
  • Medigene
  • Merck & Co.
  • Mesoblast
  • Mitsubishi Tanabe Pharma
  • Momenta
  • Morphosys
  • Mycenax Biotech
  • Mylan NV
  • Neovacs SA
  • NeuBase Therapeutics, Inc.
  • Novo Nordisk
  • Onyx Pharmaceuticals, Inc.
  • OphthaliX, Inc. Can-Fite BioPharma Ltd
  • Outlook Therapeutics, Inc.
  • Padlock
  • Pfizer
  • Philogen SpA
  • Principia Biopharma, Inc.
  • Protalex, Inc.
  • Protalix BioTherapeutics
  • Ra Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche
  • Samsung Bioepis
  • Sanofi
  • Shanghai CP Guojian Pharmaceuticals
  • Spirig Pharma A.G.
  • Takeda Pharmaceuticals
  • Theravance Biopharma, Inc.
  • TiGenix NV Takeda Pharmaceutical
  • UCB
  • Vitaeris Inc,
  • Xencor
  • XOMA
  • Zynerba Pharmaceuticals

Other Organisations Mentioned in the Report:

  • American College of Rheumatology
  • Nurses Health
  • WHO
  • National Rheumatoid Arthritis Society
  • United Nations
  • US Patent Office
  • European Commission
  • U.S. Food and Drug Administration (FDA)
  • Committee for Medicinal Products for Human Use (CHMP)
  • Centers for Disease Control and Prevention (CDC)
  • World Bank
  • Arthritis Foundation
  • Canadian Arthritis Society
  • World Arthritis Day
  • National Rheumatoid Arthritis Society
  • Servizio Sanitario Nazionale (SSN)
  • Ministry of Health
  • National Institute on Aging
  • National Center for Biotechnology Information
  • Unified Health System
  • ANVISA (Agencia Nacional de Vigilancia Sanitária)
  • African League of Associations in Rheumatology
  • International League of Associations for Rheumatology
  • Government of Abu Dhabi
  • Johns Hopkins
  • Bumrungrad
  • Cleveland Clinic
  • Vamed
  • Emirates Arthritis Foundation
  • National Treasury of Republic of South Africa
  • European Medicines Agency
  • National Institute for Health Research (NIHR)
  • National Institute for Health and Care Excellence (NICE)
  • Institute for Quality and Efficiency in Healthcare
  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen-IQWiG